You are here: Home > Prescription(RX) Drugs > A > Ampicillin (Aurobindo Pharma Limited)

Name:Ampicillin
Manufacturer:Aurobindo Pharma Limited
Category:Prescription Marketed Drugs


AMPICILLIN  - ampicillin sodium injection, powder, for solution 
Aurobindo Pharma Limited

----------

For Intramuscular or Intravenous Injection


To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin and other antibacterial drugs, ampicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION


Ampicillin for injection, USP the monosodium salt of [2S-[2α,5α,6β(S*)]]-6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, is a synthetic penicillin. It is an antibacterial agent with a broad spectrum of bactericidal activity against both penicillin-susceptible Gram-positive organisms and many common Gram-negative pathogens.
 
It has the following chemical structure:
Chemical Structure

The molecular formula is C16H18N3NaO4S, and the molecular weight is 371.39. Ampicillin for injection, USP contains 2.86 milliequivalents of sodium per 1 gram of drug.
 
Ampicillin for injection, USP is white to off-white crystalline powder. The solution after constitution is clear and colorless.

Each vial contains ampicillin sodium equivalent to 125 mg, 250 mg, 500 mg, 1 gram or 2 grams ampicillin per vial. The sodium content is 8.23 mg (0.36 mEq) per 125 mg, 16.46 mg (0.72 mEq) per 250 mg, 32.91 mg (1.43 mEq) per 500 mg, 65.83 mg (2.86 mEq) per 1 g or 131.66 mg (5.72  mEq) per 2 g of ampicillin.

CLINICAL PHARMACOLOGY


Ampicillin for injection, USP diffuses readily into most body tissues and fluids. However, penetration into the cerebrospinal fluid and brain occurs only when the meninges are inflamed. Ampicillin is excreted largely unchanged in the urine and its excretion can be delayed by concurrent administration of probenecid. The active form appears in the bile in higher concentrations than those found in serum. Ampicillin is the least serum-bound of all the penicillins, averaging about 20% compared to approximately 60 to 90% for other penicillins. Ampicillin for injection, USP is well-tolerated by most patients and has been given in doses of 2 grams daily for many weeks without adverse reactions.

Microbiology


While in vitro studies have demonstrated the susceptibility of most strains of the following organisms, clinical efficacy for infections other than those included in the INDICATIONS AND USAGE section has not been demonstrated.

The following bacteria have been shown in in vitro studies to be susceptible to ampicillin:

GRAM-POSITIVE ORGANISMS: Hemolytic and nonhemolytic streptococci, D. pneumoniae, nonpenicillinase-producing staphylococci, Clostridia spp., B. anthracis, Listeria monocytogenes, and most strains of enterococci.

GRAM-NEGATIVE ORGANISMS: H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, and many strains of Salmonella, Shigella, and E. coli.

Ampicillin does not resist destruction by penicillinase.

Susceptibility Tests


Ampicillin Susceptibility Test Discs, 10 mcg, should be used to estimate the in vitro susceptibility of bacteria to ampicillin.

INDICATIONS AND USAGE


Ampicillin for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions:

Respiratory tract Infections
caused by S. pneumoniae (formerly D. pneumoniae). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci.
 
Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.
 
Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis.

Urinary Tract Infections
caused by sensitve strains of E. coli and Proteus mirabilis.

Gastrointestinal Infections
caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy.

Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing.

It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin and other antibacterial drugs, ampicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indicated surgical procedures should be performed.

CONTRAINDICATIONS


A history of a previous hypersensitivity reaction to any of the penicillins is a contraindication.

WARNINGS


SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. ALTHOUGH ANAPHYLAXIS IS MORE FREQUENT FOLLOWING PARENTERAL THERAPY, IT HAS OCCURRED IN PATIENTS ON ORAL PENICILLINS. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH A PENICILLIN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, AMPICILLIN FOR INJECTION SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.

Clostridium difficile
associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ampicillin for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile
produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

PRECAUTIONS

General


The possibility of superinfections with mycotic organisms or bacterial pathogens should be kept in mind during therapy. In such cases, discontinue the drug and substitute appropriate treatment.

A high percentage (43 to 100 percent) of patients with infectious mononucleosis who receive ampicillin develop a skin rash. Typically, the rash appears 7 to 10 days after the start of oral ampicillin therapy and remains for a few days to a week after the drug is discontinued. In most cases, the rash is maculopapular, pruritic, and generalized. Therefore, the administration of ampicillin is not recommended in patients with mononucleosis. It is not known whether these patients are truly allergic to ampicillin.

Prescribing ampicillin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients


Patients should be counseled that antibacterial drugs including ampicillin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When ampicillin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ampicillin or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Laboratory Tests


As with any potent drug, periodic assessment of organ system function, including renal, hepatic, and hematopoietic, should be made during prolonged therapy.

Transient elevation of serum transaminase has been observed following administration of ampicillin. The significance of this finding is not known.

Drug Interactions


The concurrent administration of allopurinol and ampicillin increases substantially the incidence of skin rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

Drug/Laboratory Test Interactions


With high urine concentrations of ampicillin, false-positive glucose reactions may occur if Clinitest, Benedict's Solution, or Fehling's Solution are used. Therefore, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix or Tes-Tape) be used.

Carcinogenesis, Mutagenesis, Impairment of Fertility


No long-term animal studies have been conducted with this drug.

Pregnancy Category B


Reproduction studies have been performed in laboratory animals at doses several times the human dose and have revealed no evidence of adverse effects due to ampicillin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery


Oral ampicillin-class antibiotics are poorly absorbed during labor. Studies in guinea pigs showed that intravenous administration of ampicillin slightly decreased the uterine tone and frequency of contractions, but moderately increased the height and duration of contractions. However, it is not known whether use of these drugs in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

Nursing Mothers


Ampicillin is excreted in trace amounts in human milk. Therefore, caution should be exercised when ampicillin-class antibiotics are administered to a nursing woman.

Pediatric Use


Guidelines for the administration of these drugs to children are presented in DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS


As with other penicillins, it may be expected that untoward reactions will be essentially limited to sensitivity phenomena. They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever, or urticaria.

The following adverse reactions have been reported as associated with the use of ampicillin:

Gastrointestinal


Glossitis, stomatitis, black "hairy" tongue, nausea, vomiting, enterocolitis, pseudomembranous colitis, and diarrhea. (These reactions are usually associated with oral dosage forms.)

Hypersensitivity Reactions


Skin rashes and urticaria have been reported frequently. A few cases of exfoliative dermatitis and erythema multiforme have been reported. Anaphylaxis is the most serious reaction experienced and has usually been associated with the parenteral dosage form.

Note:
Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, ampicillin should be discontinued, unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to ampicillin therapy. Serious anaphylactic reactions require the immediate use of epinephrine, oxygen, and intravenous steroids.

Liver
A moderate rise in serum glutamic oxaloacetic transaminase (SGOT) has been noted, particularly in infants, but the significance of this finding is unknown. Mild transitory SGOT elevations have been observed in individuals receiving larger (two to four times) than usual and oft-repeated intramuscular injections. Evidence indicates that glutamic oxaloacetic transaminase (GOT) is released at the site of intramuscular injection of ampicillin sodium and that the presence of increased amounts of this enzyme in the blood does not necessarily indicate liver involvement.

Hemic and Lymphatic Systems
Anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with the penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.

OVERDOSAGE


In cases of overdose, discontinue medication, treat symptomatically, and institute supportive measures as required. In patients with renal function impairment, ampicillin-class antibiotics can be removed by hemodialysis but not peritoneal dialysis.

DOSAGE AND ADMINISTRATION


Infections of the respiratory tract and soft tissues.

Patients weighing 40 kg (88 lbs) or more: 250 to 500 mg every 6 hours.

Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.

Infections of the gastrointestinal and genitourinary tracts (including those caused by Neisseria gonorrhoeae in females).

Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours.

Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.

In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used. Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.

Urethritis in males due to N. gonorrhoeae.

Adults –
Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required.

In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months.

The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral ampicillin may be made when appropriate.

Bacterial Meningitis


Adults and children – 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours. (Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route.

Septicemia


Adults and children – 150 to 200 mg/kg/day. Start with intravenous administration for at least three days and continue with the intramuscular route every 3 to 4 hours.

Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.

DIRECTIONS FOR USE


Use only freshly prepared solutions. Intramuscular and intravenous injections should be administered within one hour after preparation since the potency may decrease significantly after this period.

For Intramuscular Use
Dissolve contents of a vial with the amount of Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP, listed in the table below:
NDC 65862 Label Claim Recommended
Amount of Diluent
Withdrawable
Volume
Concentration
(in mg/mL)
65862-231
125 mg
1.2 mL
1 mL
125 mg
65862-232
250 mg
1 mL
1 mL
250 mg
65862-233
500 mg
1.8 mL
2 mL
250 mg
65862-234
1 gram
3.5 mL
4 mL
250 mg
65862-235
2 gram
6.8 mL
8 mL
250 mg

While ampicillin for injection, USP, 1 g and 2 g, are primarily for intravenous use, they may be administered intramusculary when the 250 mg or 500 mg vials are unavailable. In such instances, dissolve in 3.5 or 6.8 mL Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP, respectively. The resulting solution will provide a concentration of 250 mg per mL.

Ampicillin for injection, USP, 125 mg, is intended primarily for pediatric use. It also serves as a convenient dosage form when small parenteral doses of the antibiotic are required.

For Direct Intravenous Use
Add 5 mL Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP to the 125, 250, and 500 mg vials and administer slowly over a 3- to 5- minute period. Ampicillin for injection, USP, 1 g or 2 g, may also be given by direct Intravenous administration. Dissolve in 7.4 or 14.8 mL Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP, respectively, and administer slowly over at least 10 to 15 minutes. CAUTION: More rapid administration may result in convulsive seizures.

For Administration by Intravenous Drip
Reconstitute as directed above (For Direct Intravenous Use) prior to diluting with Intravenous Solution. Stability studies on ampicillin sodium at several concentrations in various intravenous solutions indicate the drug will lose less than 10% activitiy at the temperatures noted for the time periods stated.
Room Temperature (25°C)
Diluent Concentrations Stability Periods
   Sterile Water for Injection
up to 30 mg/mL
8 hours
   Isotonic Sodium Chloride
up to 30 mg/mL
8 hours
   5% Dextrose in Water
10 to 20 mg/mL
1 hour
   5% Dextrose in Water
up to 2 mg/mL
2 hours
   5% Dextrose in 0.45% NaCl
up to 2 mg/mL
2 hours
   Lactated Ringer's Solution
up to 30 mg/mL
8 hours
Refrigerated (4°C)
Diluent Concentrations Stability Periods
   Sterile Water for Injection
30 mg/mL
48 hours
   Sterile Water for Injection
up to 20 mg/mL
72 hours
   Isotonic Sodium Chloride
30 mg/mL
24 hours
   Isotonic Sodium Chloride
up to 20 mg/mL
48 hours
   Lactated Ringer's Solution
up to 30 mg/mL
24 hours
   5% Dextrose in Water
up to 20 mg/mL
1 hour
   5% Dextrose and 0.45% NaCl
up to 10 mg/mL
1 hour

Only those solutions listed above should be used for the intravenous infusion of ampicillin for injection, USP. The concentrations should fall within the range specified. The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of ampicillin is administered before the drug loses its stability in the solution in use.

HOW SUPPLIED


Ampicillin for Injection, USP is white to off-white crystalline powder supplied in vials containing ampicillin sodium equivalent to 125 mg, 250 mg, 500 mg, 1 g or 2 g of ampicillin.

The following packages are available:

         NDC                                           Vial                                                       Package Factor


   65862-231-12             Ampicillin for Injection USP, 125 mg                   Box of 25 vials in 10 mL vial
   65862-232-25             Ampicillin for Injection USP, 250 mg                   Box of 25 vials in 10 mL vial
   65862-233-05             Ampicillin for Injection USP, 500 mg                   Box of 25 vials in 10 mL vial
   65862-234-01             Ampicillin for Injection USP, 1 g                          Box of 25 vials in 15 mL vial
   65862-235-02             Ampicillin for Injection USP, 2 g                          Box of 25 vials in 24 mL vial

Store the dry powder at
20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
 
Clinitest is a registered trademark of Miles, Inc.
Clinistix is a registered trademark of Bayer Corporation.
Tes-Tape is a registered trademark of Eli Lilly Company.

Manufactured for:
Aurobindo Pharma USA, Inc.
2400 Route 130 North
Dayton, NJ 08810

Manufactured by:
Aurobindo Pharma Limited
Hyderabad-500072, India

Issued: January 2009

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 125 mg Vial Label


NDC 65862-231-12
Ampicillin for Injection, USP
125 mg* per vial
Rx only         For IM or IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 125 mg Vial Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 125 mg (25 Vial) Box Label


25 Vials                  NDC 65862-231-25
Ampicillin for Injection, USP
125 mg* per vial
Rx only         For IM or IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 125 mg (25 Vial) Box Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg Vial Label


NDC 65862-232-25
Ampicillin for Injection, USP
250 mg* per vial
Rx only         For IM or IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg Vial Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg (25 Vial) Box Label


25 Vials                  NDC 65862-232-52
Ampicillin for Injection, USP
250 mg* per vial
Rx only         For IM or IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg (25 Vial) Box Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg Vial Label


NDC 65862-233-05
Ampicillin for Injection, USP
500 mg* per vial
Rx only         For IM or IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg Vial Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (25 Vial) Box Label


25 Vials                  NDC 65862-233-25
Ampicillin for Injection, USP
500 mg* per vial
Rx only         For IM or IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (25 Vial) Box Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 g Vial Label


NDC 65862-234-01
Ampicillin for Injection, USP
1 g* per vial
Rx only         For IM or IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 g Vial Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 g (25 Vial) Box Label


25 Vials                  NDC 65862-234-25
Ampicillin for Injection, USP
1 g* per vial
Rx only         For IM or IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 g (25 Vial) Box Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 2 g Vial Label


NDC 65862-235-02
Ampicillin for Injection, USP
2 g* per vial
Rx only         For IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 2 g Vial Label

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 2 g (25 Vial) Box Label


25 Vials                  NDC 65862-235-25
Ampicillin for Injection, USP
2 g* per vial
Rx only                                For IV Use
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 2 g (25 Vial) Box Label

AMPICILLIN 
ampicillin sodium injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:65862-231
Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
AMPICILLIN SODIUM (AMPICILLIN) AMPICILLIN 125 mg
Product Characteristics
Color WHITE (White to Off-white) Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:65862-231-25 25 VIAL (25 VIAL) in 1 BOX contains a VIAL (65862-231-12)
1 NDC:65862-231-12 1 INJECTION, POWDER, FOR SOLUTION (1 VIAL) in 1 VIAL This package is contained within the BOX (65862-231-25)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA065499 08/17/2010

AMPICILLIN 
ampicillin sodium injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:65862-232
Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
AMPICILLIN SODIUM (AMPICILLIN) AMPICILLIN 250 mg
Product Characteristics
Color WHITE (White to Off-white) Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:65862-232-52 25 VIAL (25 VIAL) in 1 BOX contains a VIAL (65862-232-25)
1 NDC:65862-232-25 1 INJECTION, POWDER, FOR SOLUTION (1 VIAL) in 1 VIAL This package is contained within the BOX (65862-232-52)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA065499 08/17/2010

AMPICILLIN 
ampicillin sodium injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:65862-233
Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
AMPICILLIN SODIUM (AMPICILLIN) AMPICILLIN 500 mg
Product Characteristics
Color WHITE (White to Off-white) Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:65862-233-25 25 VIAL (25 VIAL) in 1 BOX contains a VIAL (65862-233-05)
1 NDC:65862-233-05 1 INJECTION, POWDER, FOR SOLUTION (1 VIAL) in 1 VIAL This package is contained within the BOX (65862-233-25)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA065499 08/17/2010

AMPICILLIN 
ampicillin sodium injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:65862-234
Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
AMPICILLIN SODIUM (AMPICILLIN) AMPICILLIN 1 g
Product Characteristics
Color WHITE (White to Off-white) Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:65862-234-25 25 VIAL (25 VIAL) in 1 BOX contains a VIAL (65862-234-01)
1 NDC:65862-234-01 1 INJECTION, POWDER, FOR SOLUTION (1 VIAL) in 1 VIAL This package is contained within the BOX (65862-234-25)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA065499 08/17/2010

AMPICILLIN 
ampicillin sodium injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:65862-235
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
AMPICILLIN SODIUM (AMPICILLIN) AMPICILLIN 2 g
Product Characteristics
Color WHITE (White to Off-white) Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:65862-235-25 25 VIAL (25 VIAL) in 1 BOX contains a VIAL (65862-235-02)
1 NDC:65862-235-02 1 INJECTION, POWDER, FOR SOLUTION (1 VIAL) in 1 VIAL This package is contained within the BOX (65862-235-25)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA065499 08/17/2010

Labeler - Aurobindo Pharma Limited (650082092)
Establishment
Name Address ID/FEI Operations
Aurobindo Pharma Limited 918917683 MANUFACTURE

Revised: 08/2010 Aurobindo Pharma Limited



Source: http://dailymed.nlm.nih.gov
Reproduced with permission of U.S. National Library of Medicine


Copyright © 2017 Drugsdb.eu by Dionisios Fentas || Terms of Use

Loading

Prescription Marketed Drugs Alphabetically
A| B| C| D| E| F| G| H| I| J| K| L| M| N| O| P| Q| R| S| T| U| V| W| X| Y| Z| 0-9

Categories:
Prescription(RX) Drugs
Over-the-counter (OTC) Drugs
Homeopathic Drugs
Animal Drugs
Feedback